Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen

Figures & data

Table 1 Patients and treatment characteristics

Median (range) age, years	52 (32–72)
Sex
Male	50% (11/22)
Female	50% (11/22)
Histology
A	5% (1/22)
AB	22% (5/22)
B1	10% (2/22)
B2	41% (9/22)
B3	10% (2/22)
C	12% (3/22)
Stage
IIA	10% (2/22)
IIB	40% (9/22)
III	50% (11/22)
Surgery
R0	66% (14/22)
R1	34% (8/22)
Radiotherapy, Gy
44–50	32% (6/22)
50–54	34% (8/22)
60	34% (8/22)
Chemotherapy
No	85% (18/22)
Yes	15% (4/22)

Figure 1 Kaplan–Meier curves for overall survival.

Table 2 Univariate analysis

	OS rate at 3 years (%)	OS rate at 5 years (%)	P-value	RR at 3 years	RR at 5 years	P-value
Age, years
≤45	50	50	NS	50	50	0.066
>45	91.7	81.5		6.7	26.5
Sex
Male	83.3	66.7	NS	11.1	46.7	NS
Female	80	80		20	20
Histology
A/AB/B1	83.3	83.3	NS	16.7	16.7	NS
B2/B3/C	82.1	68.4		16.1	42.5
Stage
IIA/IIB	100	100	0.032	0	14.3	0.035
III	62.2	41.5		35.2	56.8
Surgery
R0	100	90	0.009	0	20	0.029
R1	47.6	0		42.9	100

Abbreviations: OS, overall survival; NS, not statistically significant; RR, relapse rate.

Table 3 Acute toxicity reported as percentages

	G1	G2	G3
Dysphagia	27%	4%
Chest pain	14%
Dyspnea	9%
Leukopenia*		14%

Note:

* Only for chemotherapy-treated patients.

Abbreviation: G, grade of toxicity.